Your browser doesn't support javascript.
loading
Women for science and science for women: Gaps, challenges and opportunities towards optimizing pre-exposure prophylaxis for HIV-1 prevention.
Karim, Quarraisha Abdool; Archary, Derseree; Barré-Sinoussi, Françoise; Broliden, Kristina; Cabrera, Cecilia; Chiodi, Francesca; Fidler, Sarah J; Gengiah, Tanuja N; Herrera, Carolina; Kharsany, Ayesha B M; Liebenberg, Lenine J P; Mahomed, Sharana; Menu, Elisabeth; Moog, Christiane; Scarlatti, Gabriella; Seddiki, Nabila; Sivro, Aida; Cavarelli, Mariangela.
Afiliação
  • Karim QA; Centre for the AIDS Programme of Research in South Africa (CAPRISA), Doris Duke Medical Research Institute (2Floor), Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa.
  • Archary D; Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, United States.
  • Barré-Sinoussi F; Centre for the AIDS Programme of Research in South Africa (CAPRISA), Doris Duke Medical Research Institute (2Floor), Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa.
  • Broliden K; Department of Medical Microbiology, School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, South Africa.
  • Cabrera C; Institut Pasteur, Paris, France.
  • Chiodi F; Department of Medicine Solna, Division of Infectious Diseases, Karolinska Institutet, Department of Infectious Diseases, Karolinska University Hospital, Center for Molecular Medicine, Stockholm, Sweden.
  • Fidler SJ; AIDS Research Institute IrsiCaixa, Institut de Recerca en Ciències de la Salut Germans Trias i Pujol (IGTP), Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Gengiah TN; Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.
  • Herrera C; Department of Infectious Disease, Faculty of Medicine, Imperial College London UK and Imperial College NIHR BRC, London, United Kingdom.
  • Kharsany ABM; Centre for the AIDS Programme of Research in South Africa (CAPRISA), Doris Duke Medical Research Institute (2Floor), Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa.
  • Liebenberg LJP; Department of Infectious Disease, Section of Virology, Faculty of Medicine, Imperial College London, London, United Kingdom.
  • Mahomed S; Centre for the AIDS Programme of Research in South Africa (CAPRISA), Doris Duke Medical Research Institute (2Floor), Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa.
  • Menu E; Department of Medical Microbiology, School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, South Africa.
  • Moog C; Centre for the AIDS Programme of Research in South Africa (CAPRISA), Doris Duke Medical Research Institute (2Floor), Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa.
  • Scarlatti G; Department of Medical Microbiology, School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, South Africa.
  • Seddiki N; Centre for the AIDS Programme of Research in South Africa (CAPRISA), Doris Duke Medical Research Institute (2Floor), Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa.
  • Sivro A; Université Paris-Saclay, Inserm, CEA, Center for Immunology of Viral, Auto-immune, Hematological and Bacterial diseases (IMVA-HB/IDMIT), Fontenay-aux-Roses & Le Kremlin-Bicêtre, France.
  • Cavarelli M; MISTIC Group, Department of Virology, Institut Pasteur, Paris, France.
Front Immunol ; 13: 1055042, 2022.
Article em En | MEDLINE | ID: mdl-36561760
ABSTRACT
Preventing new HIV infections remains a global challenge. Young women continue to bear a disproportionate burden of infection. Oral pre-exposure prophylaxis (PrEP), offers a novel women-initiated prevention technology and PrEP trials completed to date underscore the importance of their inclusion early in trials evaluating new HIV PrEP technologies. Data from completed topical and systemic PrEP trials highlight the role of gender specific physiological and social factors that impact PrEP uptake, adherence and efficacy. Here we review the past and current developments of HIV-1 prevention options for women with special focus on PrEP considering the diverse factors that can impact PrEP efficacy. Furthermore, we highlight the importance of inclusion of female scientists, clinicians, and community advocates in scientific efforts to further improve HIV prevention strategies.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Infecções por HIV / HIV-1 / Soropositividade para HIV / Fármacos Anti-HIV / Profilaxia Pré-Exposição Limite: Female / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Infecções por HIV / HIV-1 / Soropositividade para HIV / Fármacos Anti-HIV / Profilaxia Pré-Exposição Limite: Female / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article